Dexcom G7 continuous glucose monitoring (CGM) system sends real-time glucose readings automatically to a compatible smart device or receiver without the need for fingersticks
With Dexcom G7, real-time glucose readings are sent automatically to a compatible display device. (Photo: Business Wire/DexCom, Inc.)
DexCom, a developer of glucose monitoring systems for diabetes management, has received CE Mark for its Dexcom G7 continuous glucose monitoring (CGM) system indicated for people with diabetes in Europe aged two years and older, including pregnant women.
According to the company, its Dexcom G7 CGM system will help users gain better control of their diabetes.
The system, which is 60% smaller, all-in-one, discreet wearable, has been developed in collaboration with Verily.
It can complete warm-up within 30 minutes, which is claimed to be the fastest of any CGM systems available in the market.
Dexcom G7 sends real-time glucose readings automatically to a compatible smart device or receiver without the need for fingersticks.
The system also offers users a set of customisable alerts that can warn of high or low glucose levels and help them spend more time in range.
Its remote monitoring and reporting capabilities will enable users to stay connected with their loved ones and care teams anytime, anywhere.
Dexcom chairman, president and CEO Kevin Sayer said: “This all-new platform offers an incredibly powerful CGM that is simple to use, providing our users with insightful glucose data on one screen that helps them spend less time managing diabetes and more time doing the things they love.
“Dexcom G7 takes everything people love about G6 and makes it even better.”
Furthermore, the company is working with its insulin pump partners to integrate Dexcom G7 into current and future automated insulin delivery systems.
NHS England diabetes national speciality advisor Partha Kar said: “Over the past 20 years, Dexcom has been one of the leaders and pioneers in advancing real-time CGM technology.
“With enhanced features and added simplicity, Dexcom G7 will hopefully make diabetes management easier for both patients and their healthcare providers, something that is especially important as we see more and more evidence of the benefits of CGM in broader populations of those living with diabetes.”
The company is planning to start the launch of the Dexcom G7 CGM system in Europe in the next few weeks.